2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Relapsed T-Cell Lymphoma: new trials by email Literature Review of Relapsed T-Cell Lymphoma trials Research Report on Relapsed T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma CPI 613, Bendamustine - Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 6 | 2020-09-16 | 2025-05-02 |
| Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH Daratumumab - Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 8 | 2020-09-03 | 2025-03-28 |
Lymphoma, T-Cell (2) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Lymphoma, Non-Hodgkin (1)
Bendamustine Hydrochloride (1) · daratumumab (1) · devimistat (1)
Fondazione Italiana Linfomi - ETS (1) · Wake Forest University Health Sciences (1)
Italy (1) · United States (1)
Francesco Zaja (1) · Rakhee Vaidya, M.B.B.S. (1)
P30CA012197 (1)